Product Portfolio
Integrated solutions that drive sustainable growth and expand patient access worldwide.
We have a growing portfolio of pharmaceutical products designed to address critical healthcare needs across global markets. Our products are supplied through established regulatory pathways and are supported by strong manufacturing partnerships and robust quality standards.
In Partnership with theravia
Siklos® 100mg and Siklos® 1000mg tablets Hydroxyurea/hydroxycarbamide
Siklos is used for the prevention of vaso-occlusive crisis in patients aged two years and older with Sickle Cell Disease.
Markets:
- UK: Exclusive distributor
- Brazil: Local marketing authorisation holder
- GCC: Licensing and regulatory
In Partnership with Anfarm Hellas S.A.
Daptomycin 500mg vial
Bacterial antibiotic for the treatment of gram-positive infections.
Markets:
- GCC: Local marketing authorisation holder
In partnership with Anfarm Hellas S.A
Clarithromycin 500mg vial
A macrolide antibiotic used to treat various bacterial infections.
Markets:
- GCC: Local marketing authorisation holder
In partnership with Anfarm Hellas S.A
Sugammadex 100mg/ml vial
For the reversal of neuromuscular blockade induced by anaesthesia.
Markets:
- GCC: Local marketing authorisation holder
In partnership with Synchrony Pharma
Bortezomib 3.5mg vial
For the treatment of multiple myeloma and mantle cell lymphoma.
Markets:
- Central America: Local marketing authorisation holder
In partnership with Geiser Pharma
Mercaptopurine 50mg tablets
For the treatment of acute leukaemia.
Markets:
- Central America: Local marketing authorisation holder.
